AEGiS-I-BASE: Effect on tacrolimus when switching from nelfinavir to fosamprenavir Information in this article was accurate in January 2009. The state of the art may have changed since the publication date.This case report outlines the change in tacrolimus trough blood concentrations when 4 HIV-infected orthotopic liver transplant patients were switched from nelfinavir (1250 mg twice daily) to fosamprenavir (1400 mg twice daily without ritonavir) due to the EMEA ruling on nelfinavir in June 2007. After the switch, tacrolimus trough concentrations dropped significantly ( 50%) and a marked dosage increase was required to attain the desired target concentration. The cases highlight the need for caution in immunosuppressed patients when switching or starting a protease inhibitor.
